ArticlePloS one2025
Impact of pregabalin reclassification as a controlled substance in Egypt on gabapentinoid and opioid utilization: A repeated cross-sectional study.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundPregabalin is commonly used for treating pain but is also recognized for its misuse potential. In response to rising abuse, Egyptian health authorities reclassified pregabalin as a controlled substance in August 2019, aiming to curb misuse and regulate its distribution. This study evaluated the impact of the 2019 policy on gabapentinoid (pregabalin and gabapentin) and opioid sales in Egypt.
methodsAn interrupted time-series analysis using Autoregressive Integrated Moving Average (ARIMA) models was conducted on IQVIA MIDAS® quarterly volume sales data obtained under license from IQVIA for the period 2012-2023. Copyright IQVIA. All rights reserved. Drug volume sales were standardized per 1,000 individuals based on population estimates. ARIMA modelling was used to capture immediate and delayed effects of the August 2019 policy change. Percent changes for 3-, 6- and 12-months were also calculated.
resultsOverall gabapentinoid sales increased steadily until the second quarter of 2019. Following reclassification, a significant decline in total gabapentinoid sales (-67%) was observed, driven by a 99% drop in pregabalin sales, while gabapentin sales surged by 198%. ARIMA analyses of gabapentinoid sales showed a significant short-term effect (pulse: p < 0.001) and a notable gradual long-term change (ramp: p = 0.008). In contrast, opioids exhibited a significant short-term sustained increase (step: p = 0.010) but a non-significant gradual long-term change (ramp: p = 0.256), with sales rising by up to 49.5% at one year post-policy.
conclusionsReclassifying pregabalin effectively reduced its utilization but prompted a shift to gabapentin use. Our findings highlight the complexity of drug policy interventions, underscoring the need for continuous monitoring to mitigate unintended substitution effects and better understand policy impacts of the treatment of pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.